การปรับขนาดยา molnupiravir และ nirmatrelvirritonavir ในผู้ป่วยที่มีการ

Molnupiravir for the treatment of COVID-19 molnupiravir dose

In a randomized, controlled, double-blind, multidose study of the drug molnupiravir in adult outpatients with COVID-19, an 800-mg dose reduced viral RNA more

molnupiravir dose The probability of ≥30% excess toxicity over controls at 800 mg was estimated at % Conclusions Molnupiravir was safe and well tolerated; a dose of 800 mg Adults: The recommended dose of MOLNUPAC is 800 mg taken orally every 12 hours for 5 days The safety and efficacy No renal dose adjustment Dosing: Antimicrobial Dosing in Intermittent & Continuous Hemodialysis Indication Intermittent Hemodialysis Continuous Hemodialysis

ลำดับของ ฟุตบอลโลกรอบคัดเลือก โซนเอเชีย Patients were randomized to receive molnupiravir 800 mg PO twice daily for 5 days plus usual care or usual care alone The primary endpoint was